While Gerresheimer’s share price has collapsed by roughly 68 percent over the past twelve months, a notable counter-trend is emerging. Institutional investors, including the CastleKnight Master Fund and Deka Investment, have recently reported new stakes in the embattled packaging specialist. This accumulation of equity represents a high-stakes gamble on a corporate turnaround that is far from assured, set against a backdrop of a frozen financial reporting system and intense creditor negotiations.
The company’s immediate crisis stems from a blocked annual report. Germany’s financial regulator, BaFin, initiated a special audit in September 2025 and expanded its scope in early March 2026. The probe centers on flawed “bill-and-hold” agreements in the 2024 accounts, where goods were invoiced but delivered later—a clear breach of IFRS rules, resulting in a booking error of 35 million euros. Auditor Grant Thornton is now examining potential further issues in lease accounting and unimpaired asset values.
With the audited 2025 financial statements missing, Gerresheimer has breached its contractual reporting obligations, placing it in technical default. Management is in talks with lenders to secure extensions on its credit facilities. The first-quarter report and the annual shareholder meeting have been postponed indefinitely. For the pending 2025 group accounts, the company anticipates non-cash impairments of 220 to 240 million euros, primarily related to technology projects at its Sensile Medical AG unit and US-based assets.
Operationally, the firm is taking drastic steps to shore up its balance sheet. Its most profitable asset, the US prescription drug packaging subsidiary Centor, is on the block with Morgan Stanley advising on a sale targeted for completion before year-end. The unit was last valued on the books at 292 million euros. Concurrently, the Moulded Glass plant in Chicago Heights is slated for closure by the end of 2026, with production shifting to facilities in Italy and India.
Should investors sell immediately? Or is it worth buying Gerresheimer?
The fallout extends beyond operations. The German association for private investors, DSW, is exploring damage claims against former CEO Dietmar Siemssen, ex-CFO Bernd Metzner, and the audit committee of the supervisory board. The company’s expulsion from the SDAX on April 10, 2026, compounded the pressure, triggering forced selling by index-tracking funds. Furthermore, the auditor oversight body APAS has opened a professional misconduct case against former auditor KPMG, which issued an unqualified opinion on the faulty 2024 statements.
All potential recovery paths converge on a single deadline: June 2026. By then, Gerresheimer must present its audited annual financial statements. This document is the mandatory foundation for finalizing extensions with its banking partners and clearing the way for any strategic moves, including a potential takeover bid from US rival Silgan Holdings, which Reuters reported was considering an offer of 41 euros per share.
Despite the turmoil, management has issued guidance for 2026, forecasting revenues of 2.3 to 2.4 billion euros and an adjusted EBITDA margin of 18 to 19 percent. These projections, however, are explicitly conditional on securing its credit lines and a positive outcome from the BaFin investigation. Should the June deadline be missed again, the company’s negotiating leverage with creditors will shrink dramatically. The next fixed event on the calendar is the half-year report due on July 14, a milestone that remains entirely dependent on a successful June delivery. The stock, currently trading about 43 percent below its 200-day moving average, reflects the profound loss of confidence as the clock counts down.
Ad
Gerresheimer Stock: Buy or Sell?! New Gerresheimer Analysis from April 13 delivers the answer:
The latest Gerresheimer figures speak for themselves: Urgent action needed for Gerresheimer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 13.
Gerresheimer: Buy or sell? Read more here...
